Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:50AM ET
0.6456
Dollar change
+0.0346
Percentage change
5.67
%
Index- P/E- EPS (ttm)-0.91 Insider Own0.75% Shs Outstand25.94M Perf Week-3.92%
Market Cap16.75M Forward P/E- EPS next Y-0.53 Insider Trans0.00% Shs Float25.75M Perf Month-7.70%
Income-19.88M PEG- EPS next Q-0.19 Inst Own11.01% Short Float0.87% Perf Quarter-25.36%
Sales0.00M P/S- EPS this Y29.63% Inst Trans-10.88% Short Ratio2.22 Perf Half Y-43.86%
Book/sh1.39 P/B0.46 EPS next Y16.32% ROA-40.19% Short Interest0.22M Perf Year-63.32%
Cash/sh0.59 P/C1.09 EPS next 5Y- ROE-49.02% 52W Range0.53 - 2.16 Perf YTD-17.22%
Dividend Est.- P/FCF- EPS past 5Y26.09% ROI-57.84% 52W High-70.11% Beta0.93
Dividend TTM- Quick Ratio2.20 Sales past 5Y-20.00% Gross Margin- 52W Low21.18% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.20 EPS Y/Y TTM24.14% Oper. Margin0.00% RSI (14)42.13 Volatility10.17% 11.09%
Employees20 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.67
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q39.70% Payout- Rel Volume1.13 Prev Close0.61
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsMar 05 BMO Avg Volume100.46K Price0.65
SMA20-12.61% SMA50-9.71% SMA200-38.21% Trades Volume27,951 Change5.67%
Today 07:00AM
Mar-14-24 07:30AM
Mar-13-24 09:55AM
Mar-05-24 11:52PM
07:55AM
07:00AM Loading…
Feb-27-24 07:00AM
Feb-13-24 07:00AM
Feb-01-24 07:30AM
Dec-20-23 08:05AM
Dec-14-23 06:50AM
Nov-21-23 06:50AM
Nov-02-23 07:00AM
Oct-19-23 03:55PM
Oct-17-23 08:00AM
Oct-06-23 07:50AM
07:50AM Loading…
Oct-03-23 07:50AM
Sep-21-23 08:00AM
Aug-22-23 09:29AM
Jul-11-23 08:15AM
May-16-23 04:00PM
Apr-25-23 08:00AM
Apr-19-23 08:15AM
Apr-18-23 07:00AM
Mar-24-23 07:00AM
Mar-16-23 07:00AM
Feb-14-23 07:01AM
Feb-08-23 07:12AM
Feb-02-23 07:00AM
Jan-03-23 07:00AM
Nov-15-22 07:00AM
07:00AM Loading…
Nov-10-22 07:00AM
Nov-08-22 07:53AM
Nov-02-22 07:37AM
Aug-04-22 07:30AM
Jul-14-22 07:30AM
May-27-22 07:15AM
May-18-22 08:18AM
May-12-22 08:13AM
Apr-11-22 07:37AM
Feb-24-22 12:12AM
Feb-09-22 07:00AM
Feb-04-22 07:35AM
Jan-06-22 07:30AM
07:24AM
Dec-09-21 07:30AM
03:30AM
Dec-06-21 07:30AM
Nov-03-21 07:30AM
Oct-26-21 08:27AM
Oct-22-21 06:00AM
Sep-24-21 07:38AM
Sep-13-21 07:00AM
Aug-05-21 08:30AM
Jun-04-21 08:00AM
May-26-21 07:38AM
May-20-21 07:00AM
May-19-21 07:00AM
Apr-23-21 08:00AM
Apr-13-21 08:17AM
Mar-19-21 08:00AM
Mar-11-21 08:02AM
Mar-03-21 07:00AM
Mar-02-21 07:00AM
Jan-18-21 07:41AM
Jan-04-21 09:40AM
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.